Cape Town healthtech startup Alignd has raised an undisclosed amount from venture capital firm Knife Capital to take its care model beyond palliative care into maternity and kidney care.
"Knife Capital's backing, and their experience in scaling businesses locally and abroad, gives us the support to take that model into maternity and kidney care, where the need is just as urgent," said chief executive Dr Lungi Nyathi. The investment comes from Knife Fund III, the firm's third fund.
Insights on Alignd and Knife Capital
Alignd, a women-led company founded in 2018, designs what is known as value-based care. In most of South Africa's private healthcare, doctors and hospitals are paid for each consultation, test or procedure, which rewards doing more rather than achieving better results.
Alignd designs programmes for medical schemes that tie payment to the outcomes that matter to patients instead, lining up the interests of patients, providers and schemes. It started with palliative care for people with serious, life-limiting illness. That programme has built a network of more than 500 providers, works with 7 medical schemes including GEMS, Fedhealth and Bonitas, and now covers more than 3.3 million people.
The new money will scale 2 newer programmes. Its maternity programme connects expectant parents, providers and medical schemes, with support tailored to each family. Its kidney care programme coordinates care for people with chronic kidney disease, aiming to preserve kidney function for as long as possible, improve quality of life once the kidneys fail, and help schemes manage the high long-term cost of treatment such as dialysis.
Knife Capital partner Catherine Young said Alignd stood out as a women-founded team that had taken on a difficult healthcare problem and proven there was a better way to deliver care. The deal comes in a tough market: according to Dealroom, African healthtech drew just 1.3% of startup funding in the first half of 2026.
What others are saying about Alignd and Knife Capital
Disrupt Africa's Tom Jackson reported the raise and the 2 new programmes. Africa Private Equity News described Alignd's model as tying payment to outcomes that matter to patients.
TechMoran noted that Alignd's next challenge is translating its palliative care results into maternity and kidney care, where treatment, patient needs and incentives are very different.
Paying for results, not procedures
South Africa's private healthcare costs keep rising, and much of that comes from a system that pays for activity rather than results. Alignd's bet is that medical schemes will pay for programmes that keep people healthier and avoid expensive crises, and its palliative care network suggests schemes are willing to try.
Maternity and kidney care are logical next steps, because both are areas where good coordination early on can prevent very costly care later, such as emergency births or years of dialysis. They are also harder: more providers are involved, patients' needs differ widely, and the savings take longer to show. For founders in health, Alignd shows a different route to a business. Instead of building an app for patients, it sells a better way of organising care to the schemes that pay for it.
With healthtech funding so scarce, the fact that it raised at all says something about how investors see the model. It adds to a run of South African health businesses we have covered, from BioInformatiCo's clinical trial platform to the FDA-listed stappone insole.
You might also like our piece on the new physiotherapy regulations, UCT's Google-funded AI research, and Lumepay's pre-seed round.
Get more SA tech and business news and subscribe to The Open Letter.


